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Abstract
The antiretroviral agent nelﬁnavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II
trial investigated whether adding nelﬁnavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in
lenalidomide-refractory multiple myeloma (MM). Twenty-nine patients were included (high-risk cytogenetic
aberrations 31%; ≥2 prior therapy lines 93%; lenalidomide–bortezomib double-refractory 34%). Twenty-four patients
(83%) had prior bortezomib and 10 (34%) were lenalidomide–bortezomib double-refractory. They received four cycles
of nelﬁnavir 2500 mg/day with standard-dose lenalidomide (25 mg days 1–21) and dexamethasone (40/20 mg days 1,
8, 15, 22). Minor response or better was achieved in 16 patients (55%; 95% CI 36–74%), including 40% of those who
were lenalidomide–bortezomib double-refractory, and partial response or better in nine patients (31%; 95% CI
15–51%). Median progression-free survival was 3.4 (95% CI 2.0–4.9) months and median overall survival 21.6 (13.0–50.1)
months. Lenalidomide-related pneumonitis, pneumonia, and neutropenic fever occurred, but there were no
unexpected adverse events. Peripheral blood mononuclear cells showed a 45% (95% CI 40–51%) reduction in total
proteasome activity from baseline and signiﬁcant induction of unfolded protein response and autophagy. Thus,
nelﬁnavir–lenalidomide–dexamethasone is an active oral combination in lenalidomide-refractory MM.
Introduction
Despite development of new drug combinations,
including immunomodulatory drugs (pomalidomide p.o.),
proteasome inhibitors (carﬁlzomib i.v., ixazomib p.o.), and
targeted antibodies (daratumumab i.v.), for treatment of
relapsed multiple myeloma (MM), the duration of
response in double-refractory patients is only
3–5 months1–3. Thus, development of alternative mye-
loma drugs for the refractory setting in particular is an
urgent priority. Repurposing of well-known drugs
approved for use in other therapeutic settings can
potentially provide a shortcut to the development of new
myeloma treatments4. The best example of this strategy is
the success of thalidomide, which now shapes an entire
class of myeloma agents, after originally being developed
as a hypnotic agent.
Nelﬁnavir is an oral inhibitor of HIV protease, an
enzyme lacking mammalian homologs, and was a stan-
dard treatment for HIV infection for several years. It has
single-agent activity against myeloma in vivo, inducing
cell cycle arrest and apoptosis in tumor cells via multiple
pathways, including inhibition of proteasomal degrada-
tion and the PI3K/Akt pathway5–7 and importantly, by
inducing endoplasmic reticulum (ER) stress. In a phase I
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trial (SAKK 65/08)8 we showed that nelﬁnavir inhibited
proteasome activity and signiﬁcantly upregulated the
expression of proteins related to the unfolded protein
response (UPR) in peripheral blood mononuclear cells
(PMBC). This key modulator of protein production,
folding and destruction9,10, also determines proteasome
inhibitor sensitivity. Combination of nelﬁnavir with bor-
tezomib further induced the UPR and overcame protea-
some inhibitor resistance8. A subsequent phase II trial
(SAKK 39/13) demonstrated promising clinical activity of
a nelﬁnavir–bortezomib–dexamethasone combination,
with an unprecedented overall response rate of 65% in
heavily pretreated, proteasome inhibitor–refractory MM
patients11. Preclinical data indicate that nelﬁnavir was
able to overcome resistance to the proteasome inhibitor
carﬁlzomib via modulation of multidrug resistance (MDR)
efﬂux pumps such as ABCB1 (ref. 12). As lenalidomide is a
substrate of the same pump family12, and via binding to
the E3 ligase cereblon, works on the
ubiquitin–proteasome system, we postulated that nelﬁ-
navir might likewise be able to overcome resistance to
immunomodulatory drugs.
Thus, we conducted a phase I/II study to determine
whether adding nelﬁnavir to lenalidomide–dexamethasone
(Len-Dex) can overcome lenalidomide resistance in patients
with lenalidomide-refractory MM. Results from this study
have been reported previously in abstract form13.
Patients and methods
Patients with lenalidomide-refractory MM, deﬁned
according to IMWG criteria (MM that had progressed
during or within 60 days after termination of
lenalidomide-containing therapy of ≥2 months’ dura-
tion)14, were eligible for the study. They were required to
have measurable disease (serum M-protein ≥10 g/L for
IgG or ≥5 g/L for IgA, IgM, or IgD, or urine M-protein
≥200 mg/24 h) or in the absence of measurable disease,
serum immunoglobulin free light chain >100mg/L15. Also
required were adequate hematologic values (neutrophils
≥1 × 109/L and platelets ≥75 × 109/L) and hepatic function
(bilirubin ≤ 1.5 × ULN, AST, and AP ≤ 2.5 × ULN), as well
as calculated creatinine clearance >50mL/min and car-
diac ejection fraction ≥40%. Excluded were patients
receiving potent CYP3A4 modulators during the study
and those with previous grade 4 adverse events related to
lenalidomide: previous malignancy, HIV positivity, psy-
chiatric disorders, uncontrolled cardiac disease, or a ser-
ious underlying medical condition.
All patients provided written informed consent. The
trial was conducted according to applicable national and
international laws and regulations and approved by reg-
ulatory authorities (registered at ClinicalTrials.gov:
NCT01555281).
Len-Dex was administered according to a standard
schedule (Len 25 mg p.o. days 1–21; Dex 20/40 mg p.o.
days 1, 8, 15, 22). In phase I, a standard 3+ 3 dose
escalation design was used to identify the recommended
phase II dose (RP2D) of nelﬁnavir for use in combination
with Len-Dex. The nelﬁnavir dose-escalation scheme was
1250 mg orally b.i.d. (2500mg daily) for dose level (DL) 1
and 1875 mg b.i.d. (3750mg daily) for DL 2. Nelﬁnavir
was taken from days 1 to 21 of every cycle. The decision to
escalate to the next DL was based on the number of dose-
limiting toxicities (DLTs) observed in the ﬁrst cycle of
trial treatment. Persistent and late toxicities were also
considered.
In phase II nelﬁnavir was administered at the RP2D in
combination with Len-Dex (as above) for four cycles or
until progression, unacceptable toxicity, or patient with-
drawal. Response was assessed at the start of each treat-
ment cycle and conﬁrmed by a central committee. In
addition to standard IWIG response criteria14 [complete
response (CR): very good partial response (VGPR), and
partial response (PR)], we included minor response (MR),
as deﬁned by Kyle and Rajkumar:15 a ≥25% but <49%
reduction of serum M protein and reduction in 24 h urine
M protein by 50–89%, which still exceeds 200mg/24 h and
a 25–49% reduction in the size of soft tissue plasmacyto-
mas (if present at baseline) and no increase in the size or
number of lytic bone lesions. This response category is
used in patients with relapsed/refractory MM to obtain a
signal of activity in phase I/II trials of novel agents. The
primary endpoint in phase II was best response (CR,
VGPR, PR, or MR) within 16 weeks (4 cycles).
Toxicities were graded according to the National Can-
cer Institute Common Terminology Criteria for Adverse
Events (CTCAE) v.4.0.
Pharmacodynamics
Whole-blood samples were obtained from seven
patients at baseline, day 8 and day 15 of the phase I study.
PBMC were isolated and cell lysates used to test for
pharmacodynamic markers: proteasome activity was
measured in-gel after SDS-PAGE as described pre-
viously16 using a proteasome-speciﬁc, active site-directed
ﬂuorescent chemical probe17 (kindly supplied by Herman
Overkleeft, Leiden University), which visualizes both
immuno- and constitutive proteasome subunit activities.
Expression of UPR-associated proteins was evaluated
using western blot techniques after SDS-PAGE: blots for
phospho-(S724) IRE1α (Abcam, Cambridge, UK) to
evaluate activation of the main ER stress axis IRE/XBP
and blots for CCAAT-enhancer-binding protein homo-
logous protein (CHOP) (Cell Signaling Technology,
Danvers, USA) to show UPR leading to ER stress-induced
apoptosis. Blots against LC3A (Cell Signaling Technology,
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Danvers, USA) were used to evaluate autophagy. GAPDH
(Proteintech, Manchester, UK) served as a loading con-
trol. Quantitative assessments were calculated relative to
loading control using densitometry.
For the determination of proteasome activity, the
ﬂuorescent-labeled activity-based proteasome probe
(MV151) was incubated for 1 h at 37 °C with PBMC
lysates. Subsequently, the samples were denatured for
2 min at 95 °C and separated by polyacrylamide gel
electrophoresis. Proteasome activity was visualized via
quantitative assessment of the respective speciﬁc ﬂuor-
escence signals using Fusion Solo S Western Blot and
Chemi Imaging System (Vilber).
Statistical considerations
In phase II, the Simon’s two-stage design18 was used to
test the null hypothesis of a response rate (MR or better)
≤10% versus the alternative hypothesis of a response rate
≥30%. With a one-sided signiﬁcance level of 5% and a
power of 80%, a total of 29 patients (including the 6
patients from phase I treated at the RP2D) were required
with 10 patients in the ﬁrst stage and 19 more patients in
the second stage (calculated using PASS 2011, by NCSS,
Kaysville, USA). At the second-stage analysis, if at least six
patients had achieved MR or better the null hypothesis
was to be rejected and the trial regimen considered active
and promising for further investigation.
The OR rate and corresponding Clopper–Pearson 95%
conﬁdence interval (CI) were calculated. For time-to-
event endpoints median values, along with 95% CI, were
estimated using the Kaplan–Meier (KM) method. The
Wilcoxon signed-rank test was used to determine differ-
ences from baseline in pharmacodynamic parameters.
Statistical analyses were performed using SAS® 9.4 (SAS
Institute Inc., Cary, NC, USA).
Results
Patients
Between May 2012 and December 2016, 29 patients
were enrolled at seven Swiss centers. Ten patients were
included in phase I and analyzed for DLTs: two DLTs
were observed: diarrhea grade 3 and thrombocytopenia
grade 4 at a dose level of 1850mg b.i.d. Nelﬁnavir
1250 mg b.i.d. (2500mg daily) was therefore identiﬁed as
the R2PD. Twenty-nine patients were included in phase
II, including six patients from phase I.
Patient and disease characteristics for the 29 patients
are presented in Table 1. Most (93%) had undergone two
or more prior lines of therapy, and 24 (83%) had prior
bortezomib exposure, including 18 (62%) with prior
autologous stem cell transplantation and 10 (34%) who
were double-refractory to lenalidomide and bortezomib,
based on International Myeloma Working Group
(IMWG) criteria14.
Fifteen patients completed four cycles of study treat-
ment. Fourteen of 29 patients discontinued trial treatment
due to: progressive disease (PD; n= 8), unacceptable
toxicity (4), or patient refusal (2).
Response and survival
Sixteen patients (55%; 95% CI 36–74%) achieved a
response (MR or better), with VGPR in three patients
(10%), PR in six patients (21%), and MR in seven patients
Table 1 Patient characteristics
Total (n= 29)
Age (years) 64 (40–82)
Sex
Female 11 (38%)
Male 18 (62%)
Performance status
0 16 (55%)
1 12 (41%)
2 1 (3%)
Clinically signiﬁcant concomitant disease 19 (66%)
ISS stage
I 10 (34%)
II 11 (38%)
III 8 (28%)
High-risk cytogenetic aberrations t(4;16), t(14;16),
del17p
9 (31%)
Previous regimens
Number of prior lines 2 (1–7)
≥2 prior lines 27 (93%)
Autologous stem cell transplantation 18 (62%)
Lenalidomide exposure
Refractory 29 (100%)
immediate previous line of lenalidomide therapy 20 (69%)
any previous timepoint of lenalidomide therapy 9 (31%)
Progressive
While on lenalidomide therapy 24 (83%)
Within 60 days of cessation of lenalidomide therapy 5 (17%)
Median dose of lenalidomide in the last cycle prior to
enrollment (mg)
25 (10–25)
Lenalidomide+ bortezomib exposure
Exposed 24 (83%)
Refractory 10 (34%)
Data are n (%) or median (range)
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(24%). Of the remaining patients, four (14%) had stable
disease (SD), seven (24%) had PD, and two patients were
not evaluable for response analysis. Subgroup analysis
revealed seven responders among the nine patients with
high-risk cytogenetic features (78%: 1 VGPR/2 PR/4 MR)
and four responders among the 10 patients with double-
refractory disease (40%; 1 VGPR/1 PR/2 MR).
Partial response or better was achieved in 9 (31%; 95%
CI 15–51%) of patients.
Four responding patients received additional cycles
(n= 2: 3 patients; n= 7: 1 patient) of trial treatment on a
compassionate-use basis after completing the trial.
After a median follow-up of 24.9 months (interquartile
range 21.8–28.6 months), median progression-free survi-
val was 3.4 (95% CI 2.0–4.9) months, overall duration of
response 4 (1.8–5.7) months, and median overall survival
21.6 (13.0–50.1) months (Table 2).
Tolerability
The most frequent adverse events were grade 1 gas-
trointestinal symptoms (nine patients) and metabolic
disorders (nine patients). Hematologic adverse events
grade ≥3 were anemia (seven patients), thrombocytopenia
(six patients), and neutropenia (seven patients, including
two patients with febrile neutropenia). Patients with
neutropenic fever were allowed to receive treatment with
granulocyte-colony-stimulating factor.
Non-hematologic adverse events grade ≥3 were dyspnea
(three patients; unrelated to study treatment) and bone
pain grade 3 (two patients; related to traumatic iliac frac-
ture in the absence of progressive disease in one patient).
Other non-hematologic events, all judged to be possibly/
probably related to lenalidomide, were lung infection
(three patients; n= 1 grade 3/1 grade 5; proven respiratory
syncytial virus infection), pneumonitis (1 patient; grade 2),
and fatigue, a well-known adverse effect of both lenali-
domide and nelﬁnavir (13 patients; n= 3 grade 3).
Pharmacodynamics
The mechanism of action of nelﬁnavir in myeloma
therapy has not been identiﬁed. However, high con-
centrations provide proteasome inhibition in vitro16.
Lenalidomide has synergistic activity with proteasome
inhibitors in vivo19. Activity-based chemical tools were
developed that allow for a direct, speciﬁc, activity-
dependent visualization of active proteasome subunits17.
We used this tool to assess proteasome activity and
related pharmacodynamics parameters in a set of PBMC
samples from seven treated patients taken at baseline, day
8, and day 15 of cycle 1. We observed a signiﬁcant (p=
0.0156) reduction in proteasome activity in vivo, with a
51% inhibition in β2/2i (tryptic) activity, 39% in β1/1i, 5/5i
(caspase-like/chymotryptic, bortezomib-type inhibition
pattern), and 45% (95% CI 40–51%) in pan-proteasome
activity of all proteasome subunits (marizomib-type
inhibition pattern) (Fig. 1a). Most recent evidence sug-
gests that co-inhibition of β2/2i proteasome activity, in
addition to inhibition of β5/β1, is key to the activity of
proteasome inhibitors against refractory MM20. We
therefore relate the β2/2i versus β1/1i,5/5i ratios to the
clinical outcome of the seven patients: the two patients
who did not respond to treatment showed relatively poor
β2/2i co-inhibition, with a β2/β1–β5 ratio <1 (Fig. 1b).
Table 2 Response and survival outcomes (n= 29
patients)
Best response ≥MR 16 (55%, 95% CI 36–74)
Best response categories
Very good partial response (VGPR) 3 (10%)
Partial response (PR) 6 (21%)
Minor response (MR) 7 (24%)
Stable disease (SD) 4 (14%)
Progressive disease (PD) 7 (24%)
Not evaluable 2 (7%)
Best response ≥MR by subgroup
High-risk cytogenetics (n= 9) 7 (78%)
VGPR 1
PR 2
MR 4
Lenalidomide+ bortezomib; double-refractory
(n= 10)
4 (40%)
VGPR 1
PR 1
MR 2
Duration of response (months) (n= 16) 4.0 (1.8–5.7)
Overall survival (OS), median (95% CI)
(months)
21.6 (13.0–50.1)
6-month OS rate 82% (62–92)
12-month OS rate 79% (58–90)
18-month OS rate 59% (38–75)
24-month OS rate 45% 25–63)
Time to progression, median (95% CI)
(months)
3.6 (2.0–5.1)
Progression-free survival (PFS), median (95%
CI) (months)
3.4 (2.0–4.9)
4-month PFS rate 43% (25–60)
6-month PFS rate 20% (7–36)
12-month PFS rate 8% (1–22)
Data are shown as n (%), median (95% CI) or % (95% CI) unless otherwise
indicated. Median follow-up 24.9 months
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Figure 1c shows activity-based proteasome labeling in
PBMC from two representative patients and corre-
sponding densitometric analysis.
Proteasome inhibition results in myeloma cell death
through the induction of excess proteotoxic stress that
manifests in an upregulation of UPR-related proteins and
the induction of autophagy. In Fig. 2a the expression of
the ER stress protein phospho-IRE1α on day 8 and 15 is
shown relative to the clinical outcome of the 7 patients.
Interestingly, patients who had PD as best clinical
response did not exhibit increased UPR activity on day 15,
while those who maintained a substantial upregulation of
phospho-IRE1α (>100% of baseline value) responded to
treatment or showed SD. In Fig. 2b we show the densi-
tometric evaluation of western blots: mean expression of
all patients (maximum change versus before treatment)
for LC3 (mean of 305%, p= 0.031), indicating increased
autophagy, for CHOP (mean of 254%, p= 0.016), and for
activated phospho-IRE1α (to a mean of 250%, p= 0.016),
both indicating elevated ER stress. Two representative
PBMC samples are shown in Fig. 2c.
Discussion
Our phase II study shows that a combination of
standard Len-Dex with nelﬁnavir is active in patients
with lenalidomide-refractory MM, including those with
double-refractory disease. Thus, the combination of
nelﬁnavir–lenalidomide–dexamethasone overcomes
lenalidomide drug resistance in a relevant proportion of
patients. We reported earlier that the combination of
nelﬁnavir with bortezomib–dexamethasone achieved a
noteworthy 65% ORR in patients with double-refractory
MM11. Given the established safety, worldwide avail-
ability, oral route of administration, and competitive
costs of nelﬁnavir, together with its FDA-recognized
status as an orphan drug for MM, we continue to
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explore the clinical potential of re-purposing nelﬁnavir
for the treatment of patients with heavily pretreated,
refractory disease.
Nelﬁnavir–lenalidomide–dexamethasone achieved a
response rate of 55% (MR or better, 95% CI 36–74%) in
our patients with lenalidomide-refractory MM, with an
ORR of 31% (95% CI 15–51%) (i.e PR or better). High
rates of response were seen in patients with high-risk
cytogenetic aberrations (78% MR or better) and those who
were double-refractory to previous lenalidomide and
bortezomib treatment (40% MR or better). The duration
of response was 4 months in this heavily pretreated
patient population. Although the patient numbers in this
study are low and preclude deﬁnite conclusions, the
response rates are in a similar order of magnitude to the
benchmark for next-line active therapy in double-
refractory MM21. Moreover, because of the short dura-
tion of this study it is likely that the clinical beneﬁt of the
combination was underestimated—patients could receive
a maximum of only four cycles, since there was limited
external funding support for this non-commercial trial.
Treatment was well tolerated, with hematologic and non-
hematologic toxicities consistent with the expected side
effects of the individual components. Although patients
had signiﬁcant comorbidities, adverse events were man-
ageable with optimized supportive care. Nevertheless, a
small number of severe adverse events, such as a grade 2
pneumonitis, were encountered. Lung toxicity is a well-
known complication of lenalidomide, but a potential
contribution of nelﬁnavir cannot be excluded.
Active therapeutic options in the lenalidomide-refrac-
tory, and in particular in the proteasome inhibitor-
lenalidomide double-refractory MM setting, remain lim-
ited. Such patients were excluded from drug approval
trials evaluating triplets of ixazomib, daratumumab, or
carﬁlzomib in combination with lenalidomide/dex-
amethasone. Carﬁlzomib achieved a clinical beneﬁt rate
(≥MR) of 37%22, daratumumab 37%23, and pomalidomide
39%2 in heavily pretreated refractory MM patients.
Lenalidomide likewise showed synergistic activity with
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continuous low-dose cyclophosphamide, with ≥MR in
83% of patients, including those with lenalidomide- and
bortezomib-refractory disease and high-risk cytogenetic
abnormalities24.
Further studies evaluating the activity of Len-containing
triplets in Len-refractory patients are very scarce. Len-
Dex combined with daratumumab in a phase III trial
demonstrated a very high ORR of 92.9%, versus 76.4% for
the Len-Dex control group (P < 0.001). The study popu-
lation included patients exposed to lenalidomide but only
3.5% were refractory in previous lines of therapy25.
Given the lack of hematotoxicity of nelﬁnavir, it is
tempting to speculate that a quadruplet regimen of
lenalidomide, nelﬁnavir, cyclophosphamide, and dex-
amethasone might potentially provide an even more
active oral treatment option for patients with drug-
refractory MM. Pomalidomide-based triplets (Elotuzu-
mab+ Pom/Dex, Daratumumab+ Pom/Dex) have
recently been explored and appear to have a similar or
better response proﬁle than the Nelﬁnavir+ Len/Dex
regimen investigated here26,27. However, the Nelﬁnavir+
Len/Dex regimen is one of the very few all-oral combi-
nations that can provide stabilization of the disease for a
majority of patients in the relapsed-refractory setting.
Moreover, the components are available and affordable
even in countries with low/intermediate incomes, in
contrast to triplets containing pomalidomide and
antibodies.
The mechanism of activity of nelﬁnavir against MM is
not yet well established. Employing last-generation
chemical biology-based tools that directly address pro-
teasome subunit activity in patient-derived cells, we
observed a signiﬁcant inhibition of proteasome activity
and subsequent upregulation of markers of proteotoxic
stress in PBMC from patients treated with
nelﬁnavir–lenalidomide–dexamethasone in our study.
While the number of samples is small, this ﬁnding
suggests that synergy between functional proteasome
inhibition and the activity of lenalidomide might
underlie the clinical activity of the study combination.
Indeed, the degree of in vivo proteasome inhibition we
observed in PBMC during study treatment, at approxi-
mately 50% versus baseline, is quantitatively quite rele-
vant, since inhibition achieved with standard
bortezomib treatment is in the 60–70% range in clinical
trials28. Ixazomib, the only oral proteasome inhibitor
approved to date, has signiﬁcantly lower proteasome-
inhibiting activity than bortezomib, with an IC50 of
1000 nM for β5, respectively in vitro20 and, to our
knowledge, in vivo activity is yet to be reported. The
epoxyketone next-generation oral proteasome inhibitor
oprozomib has shown poor tolerability, with marked
gastrointestinal side effects29.
The nelfnavir related HIV protease inhibitor ritonavir
likewise induces proteasome inhibition at high concentra-
tions, by interfering with regulatory subunits of the pro-
teasome16. Nelﬁnavir has pan-proteasome-inhibiting
activity at high concentrations (20–40 μM) in vitro30, but
peak nelﬁnavir concentrations at the 2 × 1875mg dose are
in the 15 μM range in treated patients8. We speculate that
adding lenalidomide to nelﬁnavir treatment may increase
intracellular nelﬁnavir concentrations sufﬁciently to med-
iate the pan-proteasome-inhibiting activity seen with high
concentrations of nelﬁnavir. Both nelﬁnavir and lenalido-
mide are substrates of MDR-1 type drug efﬂux pumps12;
thus, competing interaction of the two drugs for the MDR-1
drug exporter may limit the export of nelﬁnavir in the
presence of lenalidomide. This theory is consistent with the
observation that the MTD of nelﬁnavir in combination with
bortezomib (a poor MDR-1 substrate) and dexamethasone
was 2 × 2500mg/day (ref. 8), while in our present study the
MTD was only 2 × 1250mg in combination with
lenalidomide–dexamethasone in a comparable population
of MM patients. Likewise, nelﬁnavir may have contributed
to the clinical activity of the combination therapy by
increasing intracellular lenalidomide concentrations within
myeloma cells12.
Comparison of pharmacodynamic data with clinical
outcomes in our study suggests that a relatively high
proportion of β2/2i inhibition and prolonged induction of
a proteotoxic stress response are associated with clinical
response. This is in line with the most recent notion that
co-inhibition of β2-type proteasome activity is particularly
important for the cytotoxic activity of proteasome inhi-
bitors in the drug-refractory setting, leading to enhanced
induction of proteotoxic stress, as seen with high-dose
(but not low-dose) carﬁlzomib20.
Conclusion
A combination of nelﬁnavir with Len/Dex was found to
be active in patients with lenalidomide-refractory mye-
loma, including those with lenalidomide–bortezomib
double-refractory and high-risk disease. New treatments
are urgently needed for such patients. The combination
treatment resulted in signiﬁcant proteasome inhibition
and induction of proteotoxic stress in vivo. This new
regimen offers the advantages of all-oral administration
and lower costs than those based on novel proteasome-
targeted drugs, given that nelﬁnavir is available in generic
form. These ﬁndings warrant further evaluation of
nelﬁnavir in MM.
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